SSRIs are first-line agents for the treatment of depression and anxiety and have a CPIC guideline based off their interaction with CYP2C19 and CYP2D6 (Hicks et al., 2015; Locke et al., 2015; APA, 2019). The gene discussed is CYP2D6; the disease is major depressive disorder.